Gainers
Windtree Therapeutics, Inc (NASDAQ: WINT) rose 50.7% to $0.4827 in pre-market trading after the company said Istaroxime Phase 2 study in early cardiogenic shock was published in the European Journal of Heart Failure.
According to Benzinga Pro data, during Q2, Biora Therapeutics (NASDAQ:BIOR) posted sales of $104 thousand. Earnings were up 60.07%, but Biora Therapeutics still reported an overall loss of $5.51 million.
Biora Therapeutics (NASDAQ:BIOR) is set to give its latest quarterly earnings report on Monday, 2022-08-15. Here's what investors need to know before the announcement.